Trial of CF101 to Treat Patients With Dry Eye Disease

Status Completed

Clinical Trial Summary

Eligible patients with dry eye will be treated with CF101 or placebo twice daily for 24 weeks. Disease activity will be assessed using evaluations of ocular surface integrity, tear production, and patient symptoms.

Clinical Trial Description

Patients will be randomized to receive either CF101 0.1 mg, CF101 1.0 mg, or matching placebo, given orally twice daily (BID) for 24 weeks. A Screening Period of up to 4 weeks that includes a 2-week run-in period will precede a 24-week treatment period, followed by a 2-week follow-up period. At a Screening Visit, patients will undergo complete medical and ophthalmologic history, medication history, physical examination (including height, weight, sitting blood pressure, pulse rate and temperature), ophthalmic examination, and clinical laboratory tests. Disease activity will be assessed using fluorescein staining, Schirmer test with and without anesthesia, Ocular Surface Disease Index©, and tear break-up time. Eligible patients will begin a 2-week run-in period during the 4-week screening period, during which time they will be instructed to discontinue use of all topical ophthalmic medications except for REFRESH TEARS® Lubricant Eye Drops. At the Baseline Visit, patients who successfully complete the 2-week run-in period and re-qualify for entry will be randomized to their assigned medication (CF101 0.1 mg, CF101 1.0 mg, or matching placebo) to be taken orally twice daily BID for 24 weeks. Patients will return for assessments and a new supply of study medication at Weeks 2, 4, 8, 12, 16, and 20; at Week 24 for a final on-treatment assessment; and at Week 26 for the 2-week off-treatment follow-up visit. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01235234
Study type	Interventional
Source	Can-Fite BioPharma
Contact
Status	Completed
Phase	Phase 3
Start date	July 2011
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05618730` - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B	Phase 1
Completed	`NCT02254265` - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca	Phase 2/Phase 3
Completed	`NCT00883649` - Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye	N/A
Completed	`NCT00717418` - Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease	N/A
Completed	`NCT00128245` - Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca	Phase 2
Enrolling by invitation	`NCT03436576` - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye	Phase 3
Completed	`NCT04147650` - Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome	Phase 2/Phase 3
Completed	`NCT01733992` - A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease	Phase 1
Completed	`NCT00987727` - Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye	Phase 4
Completed	`NCT00788229` - Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome	Phase 2
Completed	`NCT00554879` - Acupuncture Treatment of Dry Eye	N/A
Completed	`NCT00407043` - Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis	Phase 4
Completed	`NCT00001731` - Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops	Phase 2
Recruiting	`NCT03953703` - Levocarnitine for Dry Eye in Sjogren's Syndrome	Phase 2
Withdrawn	`NCT03398018` - Repository Corticotropin Injection in Keratoconjunctivitis Sicca	Phase 4
Recruiting	`NCT02066896` - Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome	Phase 3
Completed	`NCT02139033` - A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome	Phase 4
Terminated	`NCT01213342` - Omega-3 Fatty Acid Supplements and Dry Eye	N/A
Completed	`NCT00201981` - Study of Rebamipide Eye Drops to Treat Dry Eye	Phase 3
Completed	`NCT00201955` - Study of Rebamipide Eye Drops to Treat Dry Eye	Phase 3